Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Florida
Clinical trial register · United States · industry-sponsored

Clinical Trials in Florida, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9124 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 09 Oct 2026, 03:16 UTC
9124
Studies in scope
industry-sponsored, all four open statuses
4956
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 64 Florida 51 Illinois 32 Georgia 26 Connecticut 25
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca173 Eli Lilly and Company150 Merck Sharp & Dohme LLC117 AbbVie112 Novartis Pharmaceuticals110 Clear sponsor filter
State
California64 Florida51 Illinois32 Georgia26 Connecticut25
All 45 states
Target enrolment
to

Trials with a site in Florida

51 of 9124 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Amgen
Phase 2
15
Florida, North Carolina, Pennsylvania
2026-10-31
Recruiting
Amgen
Phase 3
159
California, Florida
2026-10-01
Recruiting
Amgen
Phase 1
308
Florida
2026-09-22
Recruiting
Amgen
Phase 3
400
Florida, Michigan, Nebraska
2026-08-28
Recruiting
Amgen
Phase 3
950
Arizona, California, Florida, Illinois, Iowa, Kansas, Louisiana, Maryland
2026-07-29
Recruiting
Amgen
Phase 3
3,200
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-23
Recruiting
Amgen
Phase 1
162
California, Florida
2026-06-11
Recruiting
Amgen
Phase 3
304
California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts
2026-05-27
Recruiting
Amgen
Phase 3
300
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2026-05-11
Recruiting
Amgen
Phase 2
30
Arkansas, Florida, Illinois, West Virginia
2026-05-07
Recruiting
Amgen
Phase 1
160
Arizona, Florida, Illinois, Minnesota, New York, Tennessee, Virginia
2026-04-21
Recruiting
Amgen
Phase 3
406
Connecticut, Florida, Kansas, Maryland, Pennsylvania, Texas
2026-03-23
Active, closed
Amgen
Phase 2
180
Arizona, California, Florida, Louisiana, Maryland, Missouri, Nevada, Texas
2026-03-05
Recruiting
Amgen
Phase 3
270
Alabama, Alaska, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Recruiting
Amgen
Phase 2
14
Florida, Texas
2026-01-02
Active, closed
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-12-19
Recruiting
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
Active, closed
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-11-25
Recruiting
Amgen
Phase 1
380
Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Missouri, New York
2025-09-16
Recruiting
Amgen
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-08-22
Active, closed
Amgen
Phase 3
350
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-08-18
Recruiting
Amgen
Phase 3
12,800
Alabama, Arizona, California, Delaware, Florida, Georgia, Idaho, Illinois
2025-07-25
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Arizona, Colorado, Florida, Louisiana, Massachusetts, Minnesota, New York, Ohio
2025-07-16
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2025-06-25
Active, closed
Amgen
Phase 1
29
California, Connecticut, Florida, Massachusetts, Missouri, North Dakota, Ohio, South Dakota
2025-05-16
Active, closed
Amgen
Phase 3
1,105
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-03-17
Active, closed
Amgen
Phase 3
3,853
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho
2025-03-12
Active, closed
Amgen
Phase 2
252
California, Connecticut, Florida, Illinois, Minnesota, New York, North Carolina, Pennsylvania
2025-02-26
Recruiting
Amgen
Phase 3
844
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey
2025-02-25
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Alabama, Arizona, California, Colorado, Connecticut, Florida, Hawaii, Illinois
2025-01-13
Active, closed
Amgen
Phase 3
707
Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan
2024-12-09
Active, closed
Amgen
Phase 2
409
Alabama, California, Florida, Georgia, Illinois, Louisiana, Michigan, Montana
2024-11-07
Active, closed
Amgen
Phase 1
21
California, Florida, Georgia, Maryland, Massachusetts, Minnesota, North Carolina, Oklahoma
2024-10-16
Active, closed
Amgen
Phase 3
315
California, Florida, Illinois, Iowa, Michigan, New York, Ohio, Texas
2024-09-09
Recruiting
Amgen
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Michigan
2024-07-17
Active, closed
Amgen
Phase 1/2
94
Arkansas, California, Florida, Illinois, Massachusetts, Nevada, Pennsylvania, Texas
2024-05-30
Active, closed
Amgen
Phase 3
111
Alabama, Arizona, California, Delaware, Florida, Georgia, Indiana, Maryland
2024-04-22
Active, closed
Amgen
Phase 3
434
Arizona, California, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2024-04-08
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
California, Connecticut, Florida, Kentucky, Louisiana, New Jersey, New York, North Carolina
2024-02-20
Recruiting
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
NCT06072482Antineutrophil Cytoplasmic Antibody-associated Vasculitis
DrugAvacopan
Amgen
Phase 4
300
Alaska, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2024-02-07
Recruiting
Amgen
Phase 3
750
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, New Mexico, New York
2023-11-16
Active, closed
Amgen
Phase 3
7,297
Alabama, Alaska, Arizona, California, Colorado, Connecticut, District of Columbia, Florida
2022-12-14
Active, closed
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05284747Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
DrugsRepatha·Evolocumab
Amgen
Phase 4
6,019
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2022-10-26
Active, closed
Amgen
Phase 1/2
329
California, Florida, Indiana, Maryland, Michigan, Missouri, New Jersey, New York
2022-02-01
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 2
222
Alabama, Arkansas, Delaware, Florida, Georgia, Iowa, Massachusetts, Michigan
2021-12-01
Active, closed
Amgen
Phase 3
303
California, Florida, Ohio, South Carolina, Texas
2021-11-02
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
California, Connecticut, District of Columbia, Florida, Kansas, North Carolina, Ohio, Pennsylvania
2020-10-15
Active, closed
Amgen
Phase 3
145
Arkansas, California, Colorado, Florida, Idaho, Illinois, Louisiana, Maryland
2020-02-26
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·TNO155·Sotorasib·Afatinib
Amgen
Phase 1
610
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2019-12-17
Active, closed
Amgen
Phase 3
457
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2019-07-19
Active, closed
Amgen
Phase 1
269
California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland, Michigan
2017-12-26
Rows per page Showing 1–51 of 51
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 October 2026. https://priyalifescience.com/clinical-trials-usa/state/florida

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,124 studies in total at the last sync on 09 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 51 of those studies with a site in Florida that also match the filters currently applied.

How many clinical trials are recruiting in Florida?

23 of the 51 studies on this page are recruiting new participants as of the 09 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 27 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Florida), 51 studies
PhaseStudiesRecruitingShare
Phase 3311560.8%
Phase 18415.7%
Phase 28315.7%
Phase 1/2203.9%
Phase 4213.9%

Most active sponsors

Lead sponsors with the most studies (Florida)
Lead sponsorStudiesRecruiting
Amgen5123
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.